# Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.

> **NCT01910038** · PHASE2 · COMPLETED · sponsor: **Centre Hospitalier Universitaire Dijon** · enrollment: 20 (actual)

## Conditions studied

- Giant Cell Arteritis

## Interventions

- **DRUG:** corticoids+ tocilizumab 8mg/Kg/4 weeks

## Key facts

- **NCT ID:** NCT01910038
- **Lead sponsor:** Centre Hospitalier Universitaire Dijon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-08
- **Primary completion:** 2015-12
- **Final completion:** 2016-06-13
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01910038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01910038, "Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01910038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*